The markets opened modestly higher with the Dow rising 33 points to 9965 after Hungary retracted comments that indicated it may face debt problems similar to Greece. Nasdaq added 5 points to 2225.
On the upside
Grifols SA will pay approximately $3.4 billion to acquire Talecris Biotherapeutics (Nasdaq: TLCR).
Bristol-Myers Squibb (NYSE: BMY) reported over the weekend that its skin cancer treatment ipilimumab increased the lifespan of patients by four months.
Sales of Sprint's (NYSE: S) HTC EVO 4G smart phone set a record for first day sales with the phone selling out at many locations.
On the downside
AspenBio Pharma (Nasdaq: APPY) must delay its Food and Drug Administration 510(k) filing for AppyScore in order to analyze additional data.
Walgreen (NYSE: WAG) will no longer accept patients with CVS Caremark (NYSE: CVS) pharmacy benefits plans.
Delcath Systems (Nasdaq: DCTH) reported over the weekend that its drug delivery system tripled the survival time of patients. The stock price dropped as investors locked in profits.
In the broad market, advancing issues outpaced decliners by a margin of nearly 2 to 1 on the NYSE and by more than 7 to 5 on Nasdaq. The Russell 2000 which tracks small cap stocks rose 4 points to 638.
